VEGF-TKI

PreclinicalSmall molecule

CCity of Hope Medical Center

VEGF-TKI is one of 29 small molecule programs targeting Kidney Cancer. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Kidney CancerActive, not recruiting

Kidney CancerPreclinical

Active, not recruiting

Competition

Competitive Landscape

31 competitors in Kidney Cancer

#DrugCompanyPhaseTrials

Opdivo

Bristol-Myers Squibb

Approved

17 2

Yervoy

Bristol-Myers Squibb

Approved

9 3

Avastin

Roche

Phase 3

21 4

Precose

Tabrecta

Votrient

11 7

Keytruda

Merck & Co.

Phase 3

8 8

Cabometyx

Bristol-Myers Squibb

Phase 3

7 9

Afinitor

Novartis

Phase 3

6 10

Osmitrol

BB. Braun Medical Inc.

Approved

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Kidney Cancer1 trial

Probiotic Yogurt Supplement in Reducing Diarrhea in Patients With Metastatic Kidney Cancer Being Treated With Vascular Endothelial Growth Factor-Tyrosine Kinase Inhibitor

Completed·—·N/A·NCT02944617·21 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for VEGF-TKI. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — VEGF-TKI compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for VEGF-TKI. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — City of Hope Medical Center company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: CCity of Hope Medical Center

VEGF-TKI

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Kidney Cancer1 trial

References

Drug Info

Quick Facts

Related News